Regen BioPharma, Inc.
RGBP
$0.00
$0.00-50.00%
OTC PK
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | 22.16% | 232.81% | 53.51% | -25.80% | 43.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 23.43% | 407.23% | 25.97% | -40.24% | 7.68% |
| Operating Income | -35.66% | -798.37% | -44.15% | 62.22% | -12.07% |
| Income Before Tax | 5,212.89% | -87.80% | -111.49% | -28.59% | 84.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5,212.89% | -87.80% | -111.49% | -28.59% | 84.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5,212.89% | -87.80% | -111.49% | -28.59% | 84.16% |
| EBIT | -35.66% | -798.37% | -44.15% | 62.22% | -12.07% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 700.00% | 92.26% | 42.33% | 54.55% | 93.96% |
| Normalized Basic EPS | 666.67% | 92.22% | 42.25% | 54.64% | 93.55% |
| EPS Diluted | 700.00% | 92.26% | 42.33% | 54.55% | 93.96% |
| Normalized Diluted EPS | 666.67% | 92.22% | 42.25% | 54.64% | 93.55% |
| Average Basic Shares Outstanding | 758.02% | 2,323.42% | 265.47% | 181.86% | 162.21% |
| Average Diluted Shares Outstanding | 758.02% | 2,323.42% | 265.47% | 181.86% | 162.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |